Early detection of prostate cancer relapse by biochemistry and diagnostic imaging

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 59, Issue 4, 2015, Pages 359-373

  Evangelista, L ^a   Zattoni, Fabio ^b   Rossi, E ^b   Karnes, R J ^c   Lowe, V ^c  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c MAYO CLINIC   (United States)

Author keywords

Circulating; Magnetic resonance imaging; Neoplastic cells; Positron emission tomography; Prostate specific antigen; Prostatic neoplasms; Tomography; Ultrasonography; X ray computed

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT;

BIOCHEMICAL RECURRENCE; BIOCHEMISTRY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SIZE; CIRCULATING TUMOR CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; DISTANT METASTASIS; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; MALE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RECURRENT DISEASE;

DIAGNOSTIC IMAGING; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 84945131939     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. Int J Cancer 2010;127:2893-917.
2. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
3. Thompson IM, Valicenti RK, Albertsen P et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 2013;190:441-9.
4. Mottet N, Bellmunt J, Briers E et al. EAU Guidelines on Prostate Cancer. Eur Urology 2015 [Epub ahead of print]
5. Roach M 3rd, Schellhammer P, Shipley WU et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. IntJ Radiat Oncol Biol Phys 2006;65:965-74.
6. Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-523.
7. Pfitzenmaier J, Pahernik S, Tremmel T et al. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int 2008;102:1413-8.
8. Mir MC, Kattan MW, Klein EA et al. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol 2014;66:204-10.
9. Zumsteg ZS, Spratt DE, Romesser PB et al. The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy. Eur Urol 2015;67:1009-16.
10. D'Amico AV, Moul J, Carroll PR et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004;172:S42-7.
11. Denham JW, Steigler A, Wilcox C et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 2008;9:1058-68.
12. Lukka H, Warde P, Pickles T et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8:1314-22.
13. Moreno JG, Croce CM, Fischer R et al. Detection of hematogenous micro-metastasis in patients with prostate cancer. Cancer Res 1992;52:6110-2.
14. Kruck S, Gakis G, Stenzl A. Circulating and disseminated tumor cells in the management of advanced prostate cancer. Adv Urol 2012;2012:135281.
15. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
16. Husemann Y, Geigl JB, Schubert F et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
17. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
18. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
19. Danila DC, Heller G, Gignac GA et al. Circulating tumour cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-8.
20. De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
21. Thalgott M, Rack B, Maurer T et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol 2013;139:755-63.
22. Loh J, Jovanovic L, Lehman M et al. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol 2014;140:2157-62.
23. Pal SK, He M, Wilson T et al. Detection and phenotypting of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer 2015;13:130-6.
24. Contreras HR, Ledezma RA, Vergara J et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and betacatenin, in prostate cancer. Urol Oncol 2010;28:534-40.
25. Gravdal K, Halvorsen OJ, Haukaas SA et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13:7003-11.
26. Lucci A, Hall CS, Lodhi AK et al. Circulating tumor cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012;13:688-95.
27. Parra RO, Wolf RM, Huben RP. The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrence after a radical pelvic operation. J Urol 1990;144:707-9.
28. Kapoor DA, Wasserman NF, Zhang G et al. Value of transrectal ultrasound identifying local after radical prostatectomy. Urology 1993;41:594-7.
29. Connolly JA, Shinohara K, Presti Jr. JC et al. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47:225-30.
30. Saleem MD, Sanders H, El Naser MA et al. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283-6.
31. Shekarriz B, Upadhyay J, Wood DP et al. Vesicouretheral anastomosis biopsy after radical prostatectomy: predicitive value of prostate specific antigen and pathologic stage. Urology 1999;54:1044-8.
32. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001;219:432-9.
33. Scattoni V, Roscigno M, Raber M et al. Multiple vesico-uretheral biopsies following radical prostatectomy: the predicitive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003;44:407-14.
34. Naya Y, Okihara K, Evans RB et al. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005;60:350-5.
35. Martino P, Scattoni V, Galosi AB et al. Role of imaging ansd biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, criotherapy, HIFU). World J Urol 2011;29:595-605.
36. Deliveliotis C, Manousakas T, Chrisofos M et al. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World Urol 2007;25:309-13.
37. Martino P, Scattoni V, Galosi AB et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 2011;29:595-605.
38. Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and post-irradiation therapy. Biomed Res Int 20l4; 20l4:3l6272.
39. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Am J Roentgenol 1997;168:379-85.
40. Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-85.
41. Casciani E, Polettini E, Carmenini E et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. Am J Roentgenol 2008;190:1187-92.
42. Cirillo S, Petracchini M, Scotti L et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19:761-9.
43. Roy C, Foudi F, Charton J et al. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. Am J Roentgenol 2013;200:W36l-W368.
44. Rouviere O, Valette O, Grivolat S et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 2004;63:922-7.
45. Pucar D, Shukla-Dave A, Hricak H et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236:545-53.
46. Sala E, Eberhardt SC, Akin O et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 2006;238:176-83.
47. Haider MA, Chung P, Sweet J et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:425-430.
48. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009;29:391-7.
49. Westphalen AC, Kurhanewicz J, Cunha RMG et al. T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol 2009;35:171-80.
50. Kim CK, Park BK, Park W et al. Prostate MR imaging at 3T using a phasedarrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdominal Imaging 2010;35:246-52.
51. Tamada T, Sone T, Jo Y et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI and T2-weighted imaging in localizing tumors. Am J Roentgenol 2011;197:408-14.
52. Kara T, Akata D, Akyol F et al. The value of dynamic contrastenhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. Diagn Interv Radiol 2011;17:38-43.
53. Akin O, Gultekin DH, Vargas HA et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011;21:1970-8.
54. Donati OF, Jung SI, Vargas HA et al. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 2013;268:440-50.
55. D'Amico AV, Crook J, Beard CJ et al. Radiation therapy for prostate cancer. In: Walsh PC, Retik AB, editors. Campbell's Urology. 8th edition. Philadelphia, PA, USA: WB Saunders; 2002. p. 3147-70.
56. Crook J, Malone S, Perry G et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355-67.
57. Paparo F, Piccardo A, Bacigalupo L, Romagnoli A, Piccazzo R, Monticone M, et al. Value of bimodal 18F-Choline-PET/MRI and trimodal 18F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy. Abdom Imaging 2015; in press
58. Sciarra A, Panebianco V, Salciccia S et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54589-600.
59. Panebianco V, Sciarra A, Lisi D et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18) F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2012;81:700-8.
60. Wu LM, Xu JR, Gu HY et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol 2013;25:252-64.
61. Panebianco V, Barchetti F, Sciarra A et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 2013;23:1745-52.
62. Picchio M, Briganti A, Fanti S et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. EurUrol 2011;59:51-60.
63. Schiavina R, Ceci F, Borghesi M et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm 2013;6:92-5.
64. Souvatzoglou M, Krause BJ, Purschel A et al. Influence of 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 2011;99:193-200.
65. Katz MS, Zelefsky MJ, Venkatraman ES et al. Predictors of biochemical outcome with salvage conformai radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-9.
66. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41.
67. Koppie TM, Grossfeld GD, Nudell DM et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 2001;166:111-5.
68. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-32.
69. Reske SN, Blumstein NM, Glatting G. [HC]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17.
70. Vees H, Buchegger F, Albrecht S et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007;99:1415-20.
71. Jilg CA, Leifert A, Schnell D et al. Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer. Radiation Oncology 2014;9:178.
72. Jilg CA, Rischke HC, Reske SN et al. Salvage Lymph Node Dissection with Adjuvant Radiotherapy for Nodal Recurrence of Prostate Cancer. J Urol 2012;188:2190-7.
73. Passoni NM, Suardi N, Abdollah F et al. Utility of [HCjcholine PET/CT in guiding lesion targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Seminars and Original Investigations 2014;32:9-16.
74. Karnes RJ, Murphy CR, Bergstralh EJ et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11ccholine positron emission tomography/computerized tomography. J Urol 2015;193:111-6.
75. Martini T, Mayr R, Trenti E et al. The role of HC-choline-PET/CT-guided secondary lymphadenectomy in patients with PSA failure after radical prostatectomy: lessons learned from eight cases. Advances in Urology 2011 1-4
76. Rigatti P, Suardi N, Briganti A et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [HCjcholine positron emission tomography/computed tomographY. Eur Urol 2011;60:935-43.
77. Rinnab L, Mottaghy FM, Simon J et al. [11 Cjcholine PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Urol Int 2008;81:191-7.
78. Winter A, Henke R-P, Wawrosche K. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urology 2015;15:10-8.
79. Von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18) F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35:221-30.
80. Marzola MC, Chondrogiannis S, Ferretti A et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med 2013;38:e26-32.
81. Mamede M, Ceci F, Castellucci P et al. The role of HC-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med 2013;38:e342-5.
82. Giovacchini G, Picchio M, Coradeschi E et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur T Nucl Med Mol Imaging 2010;37:301-9.
83. Schillaci O, Calabria F, Tavolozza M et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:589-96.
84. Castellucci P, Ceci F, Graziani T et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging HC-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014;55:1424-9.
85. Krause BJ, Souvatzoglou M, Tuncel M et al. The detection rate of [HC]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23.
86. Mitchell CR, Lowe VJ, Rangel LJ et al. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol 2013;189:1308-13.
87. Cimitan M, Evangelista L, Hodolič M et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1, 000 patients. J Nucl Med 2015;56:209-15.
88. Castellucci P, Fuccio C, Nanni C et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394-400.
89. Giovacchini G, Picchio M, Parra RG et al. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med. 2012;37:325-31.
90. Nanni C, Schiavina R, Boschi S et al. Comparison of 18F-FACBC and HC-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging 2013;40:S11-S17.
91. Nanni C, Schiavina R, Brunocilla E et al. 18F-FACBC compared with HC-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clinical Genitourinary Cancer 2014;12:106-10.
92. Savir-Baruch B, Schuster DM, Jarkas N et al. Pilot Evaluation of Anti-1-amino-2-[18F]fluorocyclopentane-1-carboxylic acid (anti-2-[18F]fACPC) PET-CT in Recurrent Prostate Carcinoma. Mol Imaging Biol 2011;13:1272-7.
93. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11-20.
94. Arce-Calisaya P, Souvatzoglou M, Eiber M et al. Sensitivity of PET/MRI to detect recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2013;40:799.
95. Wetter A, Lipponer C, Nensa F et al. Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT. Eur J Nucl Med Mol Imaging 2014;41:79-88.
96. Soyka JD, Muster MA, Schmid DT et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012;39:936-43.
97. Ceci F, Hermann K, Castellucci P et al. Impact of HC-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging 2014;41:2222-31.
98. Alongi F, Comito T, Villa E et al. What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients? Acta Oncol 2014;1:990-2.
99. Heinisch M, Dirisamer A et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA< 5 ng/ml? Mol Imaging Biol 2006;8:43-8.
100. Scattoni V, Picchio M, Suardi N et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007;52:423-9.
101. Breeuwsma AJ, Prium J, Van Den Bergh ACM et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using 11c-choline positron emission tomography. Int J Radiation Oncology Biol Phys 2010;77:160-4.
102. Winter A, Uphoff J, Henke R-P et al. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010;84:4l-23.
103. Lepinoy A, Cochet A, Cueff A et al. Pattern of occult nodal relapse diagnosed with 18F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. Radiother Oncol 2014, 111:120-5.
104. Wurschmidt F, Petersen C, Wahl A et al. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 2011;6:44.
105. Castellucci P, Fuccio C, Rubello D et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011;38:55-63.
106. Rigatti P, Suardi N, Briganti A et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11c]choline positron emission tomography/computed tomography. Eur Urol 2011;60:935-43.
107. Alongi F, Liardo RLE, Iftode C et al. 11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicity. Res Treat 2014;13:395-401.
108. Afshar-Oromieh A, Haberkorn U, Eder M et al. [68Ga]Galliumlabelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012;39:1085-6.
109. Eiber M, Maurer T, Souvatzoglou M et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015;56:668-74.
110. Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value of PET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.